IL-13-Zetakine

N/A

Report date: 2023/02/22 10:38:28

Base Information

Drug NameIL-13-Zetakine
Drug Alias NameIL-13-ZetakineSB-313-xTZSB-313
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-IL13RA2T lymphocyte replacements
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo BiosciencesCity Of Hope National Medical Center
Active IndicationsN/A
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A